Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.
Marcello Tiseo(University of Parma), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Saverio Cinieri(Ospedale A. Perrino), Francesca Zanelli(Ospedale Santa Maria), Gianni Michele Turolla(Azienda Ospedaliero-Universitaria Careggi), Francesco Grossi(University of Insubria), Anna Rita Trolese(Azienda Ospedaliero-Universitaria Careggi), Efisio Defraia, Nicoletta Zilembo(ANT Foundation Italy Onlus), Matteo Brighenti(Azienda Ospedaliero-Universitaria Careggi), Andrea Camerini(Ospedale Versilia), Carmelo Tibaldi(Azienda Ospedaliero-Universitaria Careggi), Luca Boni(Ospedale Policlinico San Martino), Claudio Dazzi(Azienda Ospedaliero-Universitaria Careggi), Editta Baldini, Vito D’Alessandro(Azienda Ospedaliero-Universitaria Careggi), Lucio Crinò(Azienda Ospedaliera di Perugia), Francesca Ambrosio(Azienda Ospedaliero-Universitaria Careggi), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 2
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|617
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
|JNCI Journal of the National Cancer Institute|2007|606